

A. Audited Financial Results for the Quarter and Year ended 31st March 2013 (Rs. in Lacs)						
Sr. No.	Particulars	Unaudited			Audited	Audited
		Quarter ended		Corresponding 3 months ended in the previous year 31.03.12	Year ended	Year Ended
		3 months ended 31.03.13	Previous 3 months ended in the current year 31.12.12		Current accounting year ended 31.03.13	Previous accounting year ended 31.03.12
		4590.55	3548.74	4003.68	12525.87	15318.19
1	Sales/Income from operation (Net of Excise duty)	26.87	0.00	54.72	104.32	60.43
2	Other Operating Income	4617.22	3548.74	4057.90	12530.19	15378.62
3	Total Net Income from Operation					
4	Expenditure					
	(a) Increase / decrease in stock in trade & work in progress	1307.56	(350.21)	(1106.54)	2005.28	(1576.15)
	(b) Consumption of raw materials	2711.32	2981.79	4781.49	8104.06	12444.85
	(c) Employees Cost	261.41	250.43	182.82	848.32	914.77
	(d) Depreciation	100.62	97.78	98.51	393.97	373.84
	(e) Other expenditure	437.34	550.40	117.94	1811.19	2126.26
	(f) Total	4818.24	3530.19	3984.12	13360.82	14283.37
5	Profit(+)/Loss(-) from operations before Other Income, Finance cost and Exceptional Items(3-4)	(201.02)	18.55	83.78	(730.63)	1095.25
		50.86	0.12	28.98	52.96	34.97
6	Other Income					
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	(150.16)	18.67	92.78	(677.67)	1130.22
		253.20	268.67	303.97	1002.24	1016.43
8	Finance Cost					
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	(403.36)	(250.00)	(211.21)	(1579.91)	113.79
		0.00	0.00	0.00	0.00	0.00
10	Exceptional Items	(403.36)	(250.00)	(211.21)	(1579.91)	113.79
11	Profit(+)/Loss(-) before Tax (9-10)	(403.36)	(250.00)	(211.21)	(1579.91)	113.79
12	Tax Expenses (incl Deferred Tax)	(499.56)	0.00	(18.56)	(489.98)	50.42
13	Net Profit(+)/Loss(-) after Tax (11-12)	96.62	(250.00)	(192.63)	(1179.93)	53.37
		0.00	0.00	0.00	0.00	0.00
14	Extraordinary Items	96.62	(250.00)	(192.63)	(1179.93)	53.37
15	Net Profit(+)/Loss(-) for the period(13-14)	1317.82	1317.82	1317.82	1317.82	1317.82
16	Paid up Equity Share Capital (face value Rs. 10/-each)				1308.40	2488.33
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					
13	Earning per share (EPS)					
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.73	(1.90)	(1.45)	(8.96)	0.48
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.73	(1.90)	(1.45)	(8.96)	0.48
14	Non Promoters Shareholding	7548453	7548453	7518063	7548453	7518063
	- Number of shares	57.28	57.28	57.05	57.28	57.05
	Percentage of shareholding					
15	Promoters and Promoter group Shareholding					
a)	Pledged/ Encumbered	5448708	5448708	1441066	5448708	1441066
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	96.78	96.78	25.45	96.78	25.48
	Percentage of Shares (as a % of the total share capital of the company)	41.35	41.35	10.94	41.35	10.94
b)	Non-encumbered	181067	181067	4219060	181067	4219060
	Number of Shares					
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	3.22	3.22	74.54	3.22	74.54
	Percentage of Shares (as a % of the total share capital of the company)	1.37	1.37	32.01	1.37	32.01

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 23rd May 2013
- The results for the quarter ended March 31, 2013 are derived figures arrived at by subtracting the results for the nine months ended on December 31, 2012 from the audited results for the year ended March 31, 2013.
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard(AS-17) "Segment Reporting" is not applicable.
- During the Quarter & Year ended 31st March 2013, 0 investor complaints were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 23.05.2013

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

Director
(Shri Govardhan M.Dhoo)



For MILWANI ASSOCIATES
Chartered Accountants

Rakesh K. Milwani Proprietor
Membership No.: 36099
F.R.N.-106405W



STATEMENT OF ASSETS & LIABILITIES AS REQUIRED UNDER CLAUSE 41 OF LISTING AGREEMENT

(Rs. In Lacs)

Particulars		As at 31 March, 2013	As at 31 March, 2012
A	EQUITY AND LIABILITIES		
1	Shareholders' funds	1,317.82	1,317.82
	(a) Share capital	1,308.40	2,488.33
	(b) Reserves and surplus	2,626.22	3,806.15
	Sub Total -Shareholders Funds		
2	Non-current liabilities	4,423.53	2,195.64
	(a) Long-term borrowings	145.27	645.25
	(b) Deferred Tax Liabilities (Net)	4,568.80	2,840.89
	Sub Total -Non-Current Liabilities		
3	Current liabilities	2,866.27	3,404.51
	(a) Short-term borrowings	1,069.44	1,268.44
	(b) Trade payables	346.52	874.54
	(c) Other current liabilities	4,282.23	5,547.49
	Sub Total -Current Liabilities	11,477.25	12,194.53
	TOTAL		
B	ASSETS		
1	I) Non-current assets	5513.36	5698.78
	(a) Fixed Assets	221.04	210.79
	(b) Long-term loans and advances	5,734.40	5,909.57
	Sub Total -Non-Current Assets		
2	Current assets	18.44	14.44
	(a) Current Investments	3,105.96	4,898.46
	(b) Inventories	2,386.57	890.99
	(c) Trade receivables	8.79	102.68
	(d) Cash and cash equivalents	223.09	378.39
	(e) Short-term loans and advances	5,742.85	6,284.96
	Sub Total -Current Assets	11,477.25	12,194.53
	TOTAL		

Notes:1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd


(Shri Govardhan M.Dhoot)

Place: Mumbai

Date: 23rd May 2013

For MILWANI ASSOCIATES
Chartered Accountants

Rakesh K. Milwani Proprietor
Membership No.: 38099
F.P.N. 105-105W



CA-Rakesh K. Milwani
B.Com., L.L.B., FCA.



MILWANI ASSOCIATES
CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel : 22036132 / 9821162679 E-mail : rakesh_milwani@hotmail.com

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement

To
Board of Directors
Mangalam Drugs & Organics Ltd.,
Mumbai

We have audited the quarterly financial results of Mangalam Drugs & Organics Ltd., for the quarter ended 31.03.2013 and the year to date results for the period 01.04.2012 to 31.03.2013, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India (Where, a listed entity is not a company) and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



CA-Rakesh K. Milwani
B.Com., L.L.B., FCA,



MILWANI ASSOCIATES
CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail : rakesh_milwani@hotmail.com

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and

(ii) give a true and fair view of the net profit/ loss (whichever is applicable) and other financial information for the quarter ended 31.03.2013 as well as the year to date results for the period from 01.04.2012 to 31.03.2013.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.



(CA RAKESH K. MILWANI)
Proprietor: MILWANI ASSOCIATES
CHARTERED ACCOUNTANTS
Membership No.036099
Firm Registration No. 106405W

Place : Mumbai

Date : 23rd May, 2013